gsk2881078
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 20, 2014 (NCT02045940)
Timeline
Indications
Studied for
Mechanism of action
- Androgen ReceptorMODULATOR
AR modulator
SARM
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545174 ↗
Also known as
- gsk2881078
- gsk2881078
- gsk2881078
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03359473 | Phase 2 | Feb 28, 2018 | GlaxoSmithKline, Parexel |
| NCT02567773 | Phase 1 | Sep 1, 2015 | GlaxoSmithKline |
| NCT02045940 | Phase 1 | Jan 20, 2014 | GlaxoSmithKline |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 3 | 3 | 2 | 2014 |
| Parexel | For profit | 1 | 0 | 1 | 2018 |
2 organizations
Page 1 / 1